Key Publications
A full list of all our publications is available on Google Scholar.
Greenland JC, Dresser K, Cutting E, Donegan R, Bond S, Crisp SJ, Scott KM, Voysey ZJ, Holbrook J, Kahanawita L, Pal R, Camacho M, Peattie ARD, Spindler LRB, Hong YT, Fryer TD, Williams-Gray CH. Azathioprine for the treatment of early Parkinson’s disease (AZA-PD): a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial. Lancet Neurol. 2026;25(1):39-49. doi:10.1016/S1474-4422(25)00386-2.
Camacho M, Greenland JC, Peattie ARD, Spindler LRB, Scott KM, Kouli A, Fryer TD, Hong YT, Solim I, Kahanawita L, Williams-Gray CH. Constipation is linked to neuroinflammation in early Parkinson’s disease. Mov Disord. 2025;41(2):e70102. doi:10.1002/mds.70102.
Patel B, Camacho M, Evans JR, Breen DP, Foltynie T, Mason SL, Cummins G, Wijeyekoon R, Barker RA, Williams-Gray CH. The rs6971 TSPO polymorphism does not influence disease presentation or progression in Parkinson’s disease. Movement Disorders. 2025. doi:10.1002/mds.70105.
Muñoz-Delgado L, Williams-Gray CH, Garraux G, Clemente D, Öztop Çakmak Ö, Greenland JC, Figueira I, Machín-Díaz I, Pirovano E, Di Flora A, Tournerie C, Papoutsopoulou S, Ertan S, Mir P, Comi C. Recommendations for clinical study protocols for immune and inflammatory profiling in Parkinson’s disease. NPJ Parkinson's Disease. 2025;11:299. doi:10.1038/s41531-025-01146-1.
Scott KM, Spindler LRB, Peattie ARD, Kouli A, Fryer TD, Hong YT, Camacho M, Solim I, Kahanawita L, Williams-Gray CH. Multimodal markers of immune activation predict cognitive outcomes in Parkinson’s disease. Brain, behavior, and immunity. 2025;129:165-78. doi: 10.1016/j.bbi.2025.05.020.
Greenland JC, Holbrook J, Kahanawita L, Camacho M, Fryer TD, Hong YT, Williams-Gray CH. Peripheral-central immune crosstalk in Parkinson’s disease and its association with clinical severity. Brain, behavior, and immunity. 2025;128:558-70. doi: 10.1016/j.bbi.2025.04.028.
Wijeyekoon RS, Camacho M, Bäckström D, Forsgren L, Lawson RA, Yarnall AJ, Macleod AD, Counsell CE, Tysnes OB, Alves G, Maple-Grødem J, Barker RA, Williams-Gray CH. Beta-adrenoceptor drugs and progression to Parkinson's disease milestones in a large pooled incident cohort. NPJ Parkinson's disease. 2025;11(1):198. doi: 10.1038/s41531-025-01014-y
Camacho M, Greenland JC, Daruwalla C, Scott KM, Patel B, Apostolopoulos D, Ribeiro J, O'Reilly M, Hu M, Williams-Gray CH. The profile of gastrointestinal dysfunction in prodromal to late-stage Parkinson’s disease. NPJ Parkinson's Disease. 2025;11(1):123. doi: 10.1038/s41531-025-00900-9.
Patel B, Greenland JC, Williams-Gray CH. Clinical Trial Highlights: Anti-Inflammatory and Immunomodulatory Agents. J Parkinsons Dis. 2024;14(7):1283-1300. doi: 10.3233/JPD-240353.
Ribeiro J, Camacho M, Scott KM, Greenland JC, Evans JR, Breen DP, Wijeyekoon RS, Barker RA, Williams-Gray CH. Validation of a 5-Year Prognostic Model for Parkinson's Disease. Mov Disord Clin Pract. 2024;11(11):1441-4. doi: 10.1002/mdc3.14215.
Lobanova, E., Zhang, Y.P., Emin, D., Brelstaff, J., Kahanawita, L., Malpetti, M., Quaegebeur, A., Triantafilou, K., Triantafilou, M., Zetterberg, H., Rowe, J.B., Williams-Gray, C.H., Bryant, C. E., Klenerman, D. ASC specks as a single-molecule fluid biomarker of inflammation in neurodegenerative diseases. Nat Commun 2024; 15(1):9690. doi: 10.1038/s41467-024-53547-0
Roodveldt C, Bernardino L, Oztop-Cakmak O, Dragic M, Fladmark KE, Ertan S, Aktas B, Pita C, Ciglar L, Garraux G, Williams-Gray C, Pacheco R, Romero-Ramos M. The immune system in Parkinson's disease: what we know so far. Brain. 2024;147(10):3306-3324. doi: 10.1093/brain/awae177.
Furlepa M, Zhang YP, Lobanova E, Kahanawita L, Vivacqua G, Williams-Gray CH, Klenerman D. Single molecule characterisation of salivary protein aggregates from Parkinson's disease patients – a pilot study. Brain Communications. 2024; 6(3), fcae178. doi: 10.1093/braincomms/fcae178.
Morris HR, Spillantini MG, Sue CM, Williams-Gray CH. The pathogenesis of Parkinson's disease. Lancet. 2024;403(10423):293-304. doi: 10.1016/S0140-6736(23)01478-2.
Kouli A, Spindler LRB, Fryer TD, Hong YT, Malpetti M, Aigbirhio FI, White SR, Camacho M, O'Brien JT, Williams-Gray CH. Neuroinflammation is linked to dementia risk in Parkinson's disease. Brain 2024;147(3):923-35. doi: 10.1093/brain/awad322.
Williams-Gray CH, Worth PF. Parkinson's disease and related conditions. Medicine. 2023;51(9):645-51. doi:10.1016/j.mpmed.2023.06.004
Gonzalez-Robles C, Bartlett M, Burnell M, Clarke CS, Haar S, Hu MT, Huxford B, Jha A, Lawton M, Noyce A, Piccini P, Pushparatnam K, Rochester L, Siu C, van Wamelen D, Williams-Gray CH, Zeissler ML, Zetterberg H, Carroll CB, Foltynie T, Weil RS, Schrag A; EJS ACT-PD Consortium. Embedding Patient Input in Outcome Measures for Long-Term Disease-Modifying Parkinson Disease Trials. Mov Disord. 2023 Dec 22. doi: 10.1002/mds.29691.
Zhang YP, Lobanova E, Emin D, Lobanov SV, Kouli A, Williams-Gray CH, Klenerman D. Imaging Protein Aggregates in Parkinson's Disease Serum Using Aptamer-Assisted Single-Molecule Pull-Down. Anal Chem. 2023; 95(41):15254-15263. doi: 10.1021/acs.analchem.3c02515.
Gonzalez-Robles C, Weil RS, van Wamelen D, Bartlett M, Burnell M, Clarke CS, Hu MT, Huxford B, Jha A, Lambert C, Lawton M, Mills G, Noyce A, Piccini P, Pushparatnam K, Rochester L, Siu C, Williams-Gray CH, Zeissler ML, Zetterberg H, Carroll CB, Foltynie T, Schrag A; EJS ACT-PD Consortium. Outcome Measures for Disease-Modifying Trials in Parkinson's Disease: Consensus Paper by the EJS ACT-PD Multi-Arm Multi-Stage Trial Initiative. J Parkinsons Dis. 2023;13(6):1011–1033. doi: 10.3233/JPD-230051.
Holbrook J, Patel B, Camacho M, Kahanawita L, Greenland J, Williams-Gray CH. Natural killer cells have an activated profile in early Parkinson's disease. Journal of neuroimmunology. 2023;382:578154. doi: 10.1016/j.jneuroim.2023.578154
Brown GC, Camacho M, Williams-Gray CH. The Endotoxin Hypothesis of Parkinson's Disease. Movement disorders 2023;38(7):1143-55. doi: 10.1002/mds.29432
Scott KM, Chong YT, Park S, Wijeyekoon RS, Hayat S, Mathews RJ, Fitzpatrick Z, Tyers P, Wright G, Whitby J, Barker RA, Hu MT, Williams-Gray CH*, Clatworthy MR*. B lymphocyte responses in Parkinson’s disease and their possible significance in disease progression. Brain Communications. 2023. doi 10.1093/braincomms/fcad060. *joint senior authors
Greenland JC, Camacho M, Williams-Gray CH. The dilemma between milestones of progression versus clinical scales in Parkinson’s disease. In: Espay AJ, editor. Precision Medicine in Neurodegenerative Disorders, Part I. Handbook of Clinical Neurology. Vol 192. Amsterdam: Elsevier 2023. p. 169-85. doi: 10.1016/B978-0-323-85538-9.00010-9
Bloem BR, Brundin P, Tan EK, Harms A, Lindestam Arlehamn C, Williams-Gray CH. Linking Immune Activation and Parkinson's Disease. Journal of Parkinson's disease. 2022;12(s1):S1-S3. doi: 10.3233/JPD-229005.
Emin D, Zhang YP, Lobanova E, Miller A, Li X, Xia Z, Dakin H, Sideris DI, Lam JYL, Ranasinghe RT, Kouli A, Zhao Y, De S, Knowles TPJ, Vendruscolo M, Ruggeri FS, Aigbirhio FI, Williams-Gray CH, Klenerman D. Small soluble alpha-synuclein aggregates are the toxic species in Parkinson's disease. Nature communications. 2022;13(1):5512.
Kouli A, Williams-Gray CH. Age-Related Adaptive Immune Changes in Parkinson's Disease. Journal of Parkinson's disease. 2022;12(s1):S93-S104.
Lobanova E, Whiten D, Ruggeri FS, Taylor CG, Kouli A, Xia Z, Emin D, Zhang YP, Lam JYL, Williams-Gray CH*, Klenerman D*. Imaging protein aggregates in the serum and cerebrospinal fluid in Parkinson's disease. Brain. 2022;145(2):632-43. (*joint senior authors)
Szwedo AA, Dalen I, Pedersen KF, Camacho M, Backstrom D, Forsgren L, Tzoulis C, Winder-Rhodes S, Hudson G, Liu G, Scherzer CR, Lawson RA, Yarnall AJ, Williams-Gray CH, Macleod AD, Counsell CE, Tysnes OB, Alves G, Maple-Grodem J, Parkinson's Incidence Cohorts C. GBA and APOE Impact Cognitive Decline in Parkinson's Disease: A 10-Year Population-Based Study. Movement Disorders. 2022;37(5):1016-27.
Kouli A, Jensen M, Papastavrou V, Scott KM, Kolenda C, Parker C, Solim IH, Camacho M, Martin-Ruiz C, Williams-Gray CH. T lymphocyte senescence is attenuated in Parkinson's disease. Journal of neuroinflammation. 2021;18(1):228.
Camacho M, Greenland JC, Williams-Gray CH. The Gastrointestinal Dysfunction Scale for Parkinson's Disease. Movement Disorders. 2021;36(10):2358-66.
Mak E, Kouli A, Holland N, Nicastro N, Savulich G, Surendranathan A, Malpetti M, Manavaki R, Hong YT, Fryer TD, Aigbirhio F, Rowe JB, O'Brien JT, Williams-Gray CH. [(18)F]-AV-1451 binding in the substantia nigra as a marker of neuromelanin in Lewy body diseases. Brain Communications. 2021;3(3):fcab177.
Camacho M, Greenland JC, Williams-Gray CH. The Gastrointestinal Dysfunction Scale for Parkinson's Disease. Movement Disorders. 2021;36(10):2358-66.
Camacho M, Macleod AD, Maple-Grodem J, Evans JR, Breen DP, Cummins G, Wijeyekoon RS, Greenland JC, Alves G, Tysnes OB, Lawson RA, Barker RA, Williams-Gray CH. Early constipation predicts faster dementia onset in Parkinson's disease. NPJ Parkinson's disease. 2021;7(1):45.
Lawson RA, Williams-Gray CH, Camacho M, Duncan GW, Khoo TK, Breen DP, Barker RA, Rochester L, Burn DJ, Yarnall AJ, ICICLE-PD study group. Which Neuropsychological Tests? Predicting Cognitive Decline and Dementia in Parkinson's Disease in the ICICLE-PD Cohort. Journal of Parkinson's disease. 2021;11(3):1297-308.
Holbrook JA, Jarosz-Griffiths HH, Caseley E, Lara-Reyna S, Poulter JA, Williams-Gray CH, Peckham D, McDermott MF. Neurodegenerative Disease and the NLRP3 Inflammasome. Frontiers in pharmacology. 2021;12(193).
Kouli A, Camacho M, Allinson K, Williams-Gray CH. Neuroinflammation and protein pathology in Parkinson’s disease dementia. Acta neuropathologica communications. 2020;8(1):211.
Greenland JC, Cutting E, Kadyan S, Bond S, Chhabra A, Williams-Gray CH. Azathioprine immunosuppression and disease modification in Parkinson's disease (AZA-PD): a randomised double-blind placebo-controlled phase II trial protocol. BMJ open. 2020;10(11):e040527.
Williams-Gray CH, Worth PF. Parkinson's disease. Medicine. 2020;48(9):595-601.
Kouli A, Williams-Gray CH. Timing Is Everything: The T-Cell Response to alpha-Synuclein Is Maximal in Early Parkinson's. Movement Disorders. 2020;35(7):1137.
Martin-Ruiz C, Williams-Gray CH, Yarnall AJ, Boucher JJ, Lawson RA, Wijeyekoon RS, Barker RA, Kolenda C, Parker C, Burn DJ, Von Zglinicki T, Saretzki G. Senescence and Inflammatory Markers for Predicting Clinical Progression in Parkinson's Disease: The ICICLE-PD Study. Journal of Parkinson's disease. 2020;10(1):193-206.
Wijeyekoon RS, Kronenberg-Versteeg D, Scott KM, Hayat S, Kuan WL, Evans JR, Breen DP, Cummins G, Jones JL, Clatworthy MR, Andres Floto R, Barker RA, Williams-Gray CH. Peripheral innate immune and bacterial signals relate to clinical heterogeneity in Parkinson's disease. Brain, behavior, and immunity. 2020;87:473-88.
Kim HJ, Mason S, Foltynie T, Winder-Rhodes S, Barker RA, Williams-Gray CH. Motor complications in Parkinson's disease: 13-year follow-up of the CamPaIGN cohort. Movement Disorders : official journal of the Movement Disorder Society. 2020;35(1):185-90.
Stoker TB, Camacho M, Winder-Rhodes S, Liu G, Scherzer CR, Foltynie T, Evans J, Breen DP, Barker RA, Williams-Gray CH. Impact of GBA1 variants on long-term clinical progression and mortality in incident Parkinson's disease. Journal of neurology, neurosurgery, and psychiatry. 2020;91(7):695-702.
Stoker TB, Camacho M, Winder-Rhodes S, Liu G, Scherzer CR, Foltynie T, Barker RA, Williams-Gray CH. A common polymorphism in SNCA is associated with accelerated motor decline in GBA-Parkinson's disease. Journal of neurology, neurosurgery, and psychiatry. 2020;91(6):673-4.
Wijeyekoon RS, Moore SF, Farrell K, Breen DP, Barker RA, Williams-Gray CH. Cerebrospinal Fluid Cytokines and Neurodegeneration-Associated Proteins in Parkinson's Disease. Movement Disorders. 2020;35(6):1062-6.
Kouli A, Horne CB, Williams-Gray CH. Toll-like receptors and their therapeutic potential in Parkinson's disease and alpha-synucleinopathies. Brain, behavior, and immunity. 2019;81:41-51.
Greenland JC, Williams-Gray CH, Barker RA. The clinical heterogeneity of Parkinson's disease and its therapeutic implications. The European journal of neuroscience. 2019;49(3):328-38
Williams-Gray CH, Wijeyekoon RS, Scott KM, Hayat S, Barker RA, Jones JL. Abnormalities of age-related T cell senescence in Parkinson's disease. Journal of neuroinflammation. 2018;15(1):166.
Wijeyekoon RS, Kronenberg-Versteeg D, Scott KM, Hayat S, Jones JL, Clatworthy MR, Floto RA, Barker RA, Williams-Gray CH. Monocyte Function in Parkinson's Disease and the Impact of Autologous Serum on Phagocytosis. Frontiers in neurology. 2018;9(870).
White AJ, Wijeyekoon RS, Scott KM, Gunawardana NP, Hayat S, Solim IH, McMahon HT, Barker RA, Williams-Gray CH. The Peripheral Inflammatory Response to Alpha-Synuclein and Endotoxin in Parkinson's Disease. Frontiers in neurology. 2018;9(946).
Scott KM, Kouli A, Yeoh SL, Clatworthy MR, Williams-Gray CH. A Systematic Review and Meta-Analysis of Alpha Synuclein Auto-Antibodies in Parkinson's Disease. Frontiers in neurology. 2018;9(815).
Williams-Gray CH, Barker RA. Parkinson disease: Defining PD subtypes - a step toward personalized management? Nature Reviews Neurology. 2017;13(8):454-5.
Liu G, Locascio JJ, Corvol JC, Boot B, Liao Z, Page K, Franco D, Burke K, Jansen IE, Trisini-Lipsanopoulos A, Winder-Rhodes S, Tanner CM, Lang AE, Eberly S, Elbaz A, Brice A, Mangone G, Ravina B, Shoulson I, Cormier-Dequaire F, Heutink P, van Hilten JJ, Barker RA, Williams-Gray CH, Marinus J, Scherzer CR. Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohorts. Lancet Neurology. 2017;16(8):620-29.
Lawson RA, Yarnall AJ, Duncan GW, Breen DP, Khoo TK, Williams-Gray CH, Barker RA, Burn DJ, ICICLE-PD study group. Stability of mild cognitive impairment in newly diagnosed Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry. 2017;88(8):648-52.
Collins LM, Williams-Gray CH. The Genetic Basis of Cognitive Impairment and Dementia in Parkinson’s Disease. Frontiers in Psychiatry 2016; 7:89.
Williams-Gray CH, Wijeyekoon R, Yarnall AJ, Lawson RA, Breen DP, Evans JR, Cummins GA, Duncan GW, Khoo TK, Burn DJ, Barker RA, ICICLE-PD study group. Serum immune markers and disease progression in an incident Parkinson’s disease cohort (ICICLE-PD). Movement Disorders. 2016; 31(7):995-1003
Velseboer DC, de Bie RM, Wieske L, Evans JR, Mason SL, Foltynie T, Schmand B, de Haan RJ, Post B, Barker RA, Williams-Gray CH. Development and external validation of a prognostic model in newly diagnosed Parkinson disease. Neurology 2016;86(11):986-93
Evans JR, Cummins G, Breen DP, Foltynie T, Mason SL, Brayne CE, Williams-Gray CH, Barker RA. Comparative epidemiology of incident Parkinson's disease in Cambridgeshire, UK. Journal of Neurology, Neurosurgery and Psychiatry. 2016; 87(9):1034-6.
Barker RA, Williams-Gray CH. The spectrum of clinical features seen with alpha synuclein pathology. Neuropathology and Applied Neurobiology. 2016; 42(1):6-19.
Lawson RA, Yarnall AJ, Duncan GW, Breen DP, Khoo TK, Williams-Gray CH, Barker RA, Collerton D, Taylor JP, Burn DJ, ICICLE-PD study group. Cognitive decline and quality of life in incident Parkinson's disease: The role of attention. Parkinsonism & related disorders. 2016;27:47-53.
Liu G, Boot B, Locascio JJ, Jansen IE, Winder-Rhodes S, Eberly S, Elbaz A, Brice A, Ravina B, van Hilten JJ, Cormier-Dequaire F, Corvol JC, Barker RA, Heutink P, Marinus J, Williams-Gray CH, Scherzer CR, International Genetics of Parkinson Disease Progression Consortium. Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's. Annals of Neurology. 2016;80(5):674-85.
Winder-Rhodes SE. Barker RA, Williams-Gray CH. The pathological and prognostic heterogeneity of Mild Cognitive Impairment in Parkinson’s disease. In: Emre M, editor. Cognitive Impairment and Dementia in Parkinson’s Disease, 2nd Edition. Oxford University Press, 2015: 223-240.
Barker RA, Williams-Gray CH. Mild Cognitive Impairment and Parkinson's Disease - Something to Remember. Journal of Parkinson's disease 2014;4(4):651-656.
Moore SF, Guzman NV, Mason SL, Williams-Gray CH, Barker RA. Which Patients with Parkinson's Disease Participate in Clinical Trials? One Centre's Experiences with a New Cell Based Therapy Trial (TRANSEURO). Journal of Parkinson's disease 2014;4(4):671-676.
Goldman JG, Williams-Gray C, Barker RA, Duda JE, Galvin JE. The spectrum of cognitive impairment in Lewy body diseases. Movement Disorders 2014;29:608-21.
Williams-Gray CH, Mason SL, Evans JR, Foltynie T, Brayne C, Robbins TW, Barker RA. The CamPaIGN study of Parkinson’s disease: 10 year outlook in an incident population-based cohort. Journal of Neurology, Neurosurgery and Psychiatry. 2013; 84(11):1258-64
Rittman T, Ghosh BC, McColgan P, Breen DP, Evans J, Williams-Gray CH, Barker RA, Rowe JB. The Addenbrooke's Cognitive Examination for the differential diagnosis and longitudinal assessment of patients with parkinsonian disorders. Journal of Neurology, Neurosurgery and Psychiatry. 2013; 84(5):544-51.
Breen DP, Williams-Gray CH, Mason SL, Foltynie T, Barker RA. Excessive daytime sleepiness and its risk factors in incident Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry. 2013; 84(2):233-4.
Winder-Rhodes SE, Evans JR, Ban M, Mason SL, Williams-Gray CH, Foltynie T, Duran R, Mencacci NE, Sawcer SJ, Barker RA. Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. Brain. 2013;136:392-9.
Williams-Gray CH, Barker RA. The genetics of behaviour and cognition in Parkinson’s disease. In: Aarsland D, Cummings J, Weintraub D, and Chaudhuri R, editors. Neuropsychiatric and cognitive changes in Parkinson's disease and related Movement Disorders: diagnosis and management. Cambridge University Press, 2013:25-39.
Fallon SJ, Williams-Gray CH, Barker RA, Owen AM, Hampshire A. Prefrontal Dopamine Levels Determine the Balance between Cognitive Stability and Flexibility. Cerebral Cortex. 2013; 23(2):361-9.
McColgan P, Evans J, Breen DP, Mason SL, Barker RA, Williams-Gray CH. Addenbrooke’s Cognitive Examination-Revised for Mild Cognitive Impairment in Parkinson’s disease. Movement Disorders 2012; 27(9):1173-7.
Litvan I, Goldman JG, Troster AI, Schmand BA, Weintraub D, Petersen RC, Mollenhauer B, Adler CH, Marder K, Williams-Gray CH, Aarsland D, Kulisevsky J, Rodriguez-Oroz MC, Burn DJ, Barker RA, Emre M. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Movement Disorders 2012; 27(3):349-56.
Williams-Gray CH, Mason SL. Neuropsychological features of early cognitive impairment in Parkinson’s disease. In: Ebmeier KP, O’Brien J, Taylor JP, editors. Psychiatry of Parkinson's disease. Advances in Biological Psychiatry. Vol 27. Basel: Karger, 2012: 84-102.
Evans JR, Mason SL, Williams-Gray CH, Foltynie T, Brayne C, Robbins TW, Barker RA. The natural history of treated Parkinson's disease in an incident, community based cohort. Journal of Neurology, Neurosurgery and Psychiatry 2011; 82(10): 1112-8.
Aarsland D, Bronnick K, Williams-Gray C, Weintraub D, Marder K, Kulisevsky J, Burn D, Barone P, Pagonabarraga J, Allcock L, Santangelo G, Foltynie T, Janvin C, Larsen JP, Barker RA, Emre M. Mild cognitive impairment in Parkinson disease: A multicenter pooled analysis. Neurology 2010; 75: 1062-9.
Saiki M, Baker A, Williams-Gray CH, Foltynie T, Goodman RS, Taylor CJ, Compston DA, Barker RA, Sawcer SJ, Goris A. Association of the human leucocyte antigen region with susceptibility to Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry 2010; 81: 890-1.
Williams-Gray CH, Evans JR, Goris A, Foltynie T, Ban M, Robbins TW, Brayne C, Kolachana BS, Weinberger DR, Sawcer SJ, Barker RA. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 2009; 132: 2958-69.
Williams-Gray CH, Goris A, Saiki M, Foltynie T, Compston DA, Sawcer SJ, Barker RA. Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's disease. Journal of Neurology 2009; 256: 493-8.
Williams-Gray CH, Goris A, Foltynie T, Compston DAS, Sawcer SJ, Barker RA. No evidence for association between an MAOA functional polymorphism and susceptibility to Parkinson’s disease. Journal of Neurology 2009; 256:493-8.
Williams-Gray CH, Hampshire A, Barker RA, Owen AM. Attentional control in Parkinson's disease is dependent on COMT val158met genotype. Brain 2008; 131:397-408.
Wedderburn C, Wear H, Brown J, Mason SJ, Barker RA, Hodges JR, Williams-Gray, CH. The utility of the Cambridge Behavioural Inventory in neurodegenerative disease. Journal of Neurology, Neurosurgery and Psychiatry 2008; 79:500-503.
Wear HJ, Wedderburn CJ, Mioshi E, Williams-Gray CH, Mason SL, Barker RA, Hodges JR. The Cambridge Behavioural Inventory revised. Dementia and Neuropsychologia 2008; 2:102-107.
Rowe JB, Hughes L, Ghosh BC, Eckstein D, Williams-Gray CH, Fallon S, Barker RA, Owen AM. Parkinson's disease and dopaminergic therapy - differential effects on movement, reward and cognition. Brain 2008; 131: 2094-105.
Williams-Gray CH, Hampshire A, Robbins TW, Owen AM, Barker RA. COMT val158met genotype influences frontoparietal activity during planning in patients with Parkinson’s disease. Journal of Neuroscience 2007;27:4832-8.
Williams-Gray CH, Foltynie T, Brayne CEG, Robbins TW, Barker RA. The evolution of cognitive dysfunction in an incident Parkinson’s disease cohort. Brain 2007;130:1787-98.
Williams-Gray CH, Barker RA. Visual hallucinations predict increased benefits from rivastigmine in Parkinson's disease dementia. Nature Clinical Practice Neurology 2007;3:250-1.
Williams-Gray CH, Aliyu S, Lever AML, Dean AF, Lennox GG. Reversible parkinsonism in a patient with progressive multifocal leucoencephalopathy. Journal of Neurology, Neurosurgery and Psychiatry 2007;78:408-10.
Goris A,* Williams-Gray CH,* Clark GR, Foltynie T, Lewis SJ, Brown J, Ban M, Spillantini MG, Compston A, Burn DJ, Chinnery PF, Barker RA, Sawcer SJ. Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. Annals of Neurology 2007; 62:145-153 (* Joint first authors).
Goris A,* Williams-Gray CH,* Foltynie T, Brown J, Maranian M, Walton A, Compston DAS, Barker RA, Sawcer SJ. Investigation of TGFB2 as a candidate gene in Multiple Sclerosis and Parkinson’s disease. Journal of Neurology 2007;254:846-8 (* Joint first authors).
Williams-Gray CH, Goris A, Foltynie T, Brown J, Maranian M, Walton A, Compston DA, Sawcer SJ, Barker RA. Prevalence of the LRRK2 G2019S mutation in a UK community based idiopathic Parkinson's disease cohort. Journal of Neurology, Neurosurgery and Psychiatry 2006;77(5):665-667.
Williams-Gray CH, Goris A, Foltynie T, Brown J, Maranian M, Walton A, Compston DA, Sawcer SJ, Barker RA. No alterations in alpha-synuclein gene dosage observed in sporadic Parkinson's disease. Movement Disorders 2006;21(5):731-732
Williams-Gray CH, Foltynie T, Lewis SJ, Barker RA. Cognitive deficits and psychosis in Parkinson's disease: a review of the pathophysiology and therapeutic options. CNS Drugs 2006;20(6):477-505.
Williams-Gray C, Barker RA, Swainson R, Robbins TW. Cognitive dysfunction in early Parkinson's disease. In: Wolters EC, Berendse H, Stam C, editors. Mental Dysfunction in Parkinson's disease III: VU University Press, 2006: 109-120.